Stockscreener 앱 받기
28.59
2.65%
0.89
시간 외 거래:
28.56
-0.03
-0.10%
전일 마감가:
$27.70
열려 있는:
$27.77
하루 거래량:
96,039
Relative Volume:
1.00
시가총액:
$301.66M
수익:
$96.10M
순이익/손실:
$-31.96M
주가수익비율:
-7.1001
EPS:
-4.0267
순현금흐름:
$-25.27M
1주 성능:
+5.00%
1개월 성능:
+18.48%
6개월 성능:
+64.46%
1년 성능:
+333.46%
1일 변동 폭
$27.55
$29.00
1주일 범위
$25.60
$29.00
52주 변동 폭
$5.26
$31.31
바이오데식스 Stock (BDSX) Company Profile
명칭
Biodesix Inc
전화
303-417-0500
주소
919 WEST DILLON ROAD, LOUISVILLE
Compare BDSX vs TMO, DHR, NTRA, IQV, A
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BDSX
Biodesix Inc
|
28.59 | 284.51M | 96.10M | -31.96M | -25.27M | -4.0267 |
TMO
Thermo Fisher Scientific Inc
|
648.55 | 225.48B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
208.52 | 140.70B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
345.32 | 47.41B | 2.50B | -226.32M | 71.51M | -1.6412 |
IQV
Iqvia Holdings Inc
|
269.06 | 43.09B | 16.63B | 1.39B | 2.12B | 8.0674 |
A
Agilent Technologies Inc
|
153.62 | 41.42B | 7.23B | 1.41B | 1.09B | 4.979 |
바이오데식스 Stock (BDSX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-27 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2025-05-14 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2024-09-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-07-26 | 개시 | Craig Hallum | Buy |
| 2024-05-13 | 개시 | TD Cowen | Buy |
| 2024-05-03 | 개시 | Lake Street | Buy |
| 2021-11-17 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-11-23 | 개시 | BTIG Research | Buy |
| 2020-11-23 | 개시 | Canaccord Genuity | Buy |
| 2020-11-23 | 개시 | Morgan Stanley | Overweight |
| 2020-11-23 | 개시 | William Blair | Outperform |
모두보기
바이오데식스 주식(BDSX)의 최신 뉴스
A Look at Biodesix Inc (BDSX) After 3.5% Gain -- GF Value $21.14 vs Price $26.96 - GuruFocus
Opaleye Management Inc. Cuts Position in Biodesix, Inc. $BDSX - marketbeat.com
Biodesix: Growing Fast While Trading Below Many Diagnostics Peers (NASDAQ:BDSX) - Seeking Alpha
Biodesix, Inc. (NASDAQ:BDSX) Given Consensus Recommendation of "Moderate Buy" by Analysts - marketbeat.com
BlackRock Inc. Invests $970,000 in Biodesix, Inc. $BDSX - marketbeat.com
Biodesix Stock Price Forecast. Should You Buy BDSX? - StockInvest.us
Biodesix to Participate in Upcoming Investor Conferences - The Manila Times
Biodesix Inc (NASDAQ: BDSX) Stock Price, News & Analysis - kalkine.ca
BioDesix (NASDAQ:BDSX) Passes Minervini Trend Template but Setup Quality Remains Weak - ChartMill
What Makes Biodesix, Inc. (BDSX) a Strong Momentum Stock: Buy Now? - Yahoo Finance
Biodesix Inc (BDSX) Stock Up 9.0% but GF Value Says Overvalued -- GF Score: 51/100 - GuruFocus
Does Biodesix (BDSX) Have the Potential to Rally 103.33% as Wall Street Analysts Expect? - qz.com
PRPO vs. BDSX: Which Cancer Diagnostics Stock Is the Better Buy Now? - The Globe and Mail
Biodesix (BDSX) Q2 2026 Results: The Bottom-Line Figure Outpaces Its Comparison on the Day; After Earnings: The Stock Loses 5.91% in the Latest SessionCEO Earnings Statement - vinanet.vn
Biodesix (BDSX) Results Check: The Bottom-Line Figure Beats Its Comparison; After Earnings: The Market Price Declines 3.91% in Latest TradingGuidance Accuracy Score - vinanet.vn
46,989 Shares in Biodesix, Inc. $BDSX Purchased by GSA Capital Partners LLP - MarketBeat
AIGH Capital Management LLC Acquires New Stake in Biodesix, Inc. $BDSX - MarketBeat
Biodesix (BDSX) Edges Higher at $24.0 as Bulls Defend Key SupportVol Target Rebalance - vinanet.vn
Walleye Capital LLC Makes New $1.68 Million Investment in Biodesix, Inc. $BDSX - MarketBeat
Sei Investments Co. Makes New Investment in Biodesix, Inc. $BDSX - MarketBeat
BDSX Q2 2026 Earnings: EPS Beats Estimates by 22.85% as Loss NarrowsEarnings Preview - vinanet.vn
BDSX | Biodesix, Inc. Common Stock FinancialsRevenue Breakdown - Quiver Quantitative
Biodesix director Jack Schuler buys company stock, valued at $366,991 By Investing.com - Investing.com Australia
Biodesix director Jack Schuler buys company stock, valued at $366,991 - Investing.com
BDSX Q2 2026 Earnings: Narrower Loss Beats Estimates as Shares Dip 1.78Earnings Yield Spread - Vinanet
Biodesix (NASDAQ:BDSX) Director Jack Schuler Buys 15,000 Shares of Stock - MarketBeat
Biodesix Insider Bought Shares Worth $366,992, According to a Recent SEC Filing - marketscreener.com
Biodesix Inc (BDSX) major holder Jack W. Schuler buys 15,000 shares - Stock Titan
Biodesix, Inc. (NASDAQ:BDSX) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Biodesix director Jack Schuler buys $665,940 in company stock By Investing.com - Investing.com Australia
Biodesix (NASDAQ:BDSX) Director Jack Schuler Purchases 13,700 Shares of Stock - MarketBeat
Insider Buying: Biodesix (NASDAQ:BDSX) Director Purchases 13,900 Shares - MarketBeat
Biodesix director Jack Schuler buys $665,940 in company stock - Investing.com India
Biodesix at Canaccord Genuity conference: growth, margins in focus By Investing.com - Investing.com Nigeria
Biodesix (BDSX) Q2 2026 Earnings Call Transcript - The Globe and Mail
Biodesix (BDSX) major holder Jack W. Schuler adds shares via trusts - Stock Titan
Biodesix Sees Nodify Growth, Reaffirms Revenue Outlook at Canaccord Conference - TradingView
Biodesix, Inc. (BDSX) Hit a 52 Week High, Can the Run Continue? - Yahoo Finance
Canaccord raises Biodesix stock price target on strong test volume By Investing.com - Investing.com India
Wall Street Analysts Think Biodesix (BDSX) Could Surge 31.91%: Read This Before Placing a Bet - Yahoo Finance
BDSX Maintained by Canaccord Genuity -- Price Target Raised to $35 - GuruFocus
Canaccord Genuity Group Issues Positive Forecast for Biodesix (NASDAQ:BDSX) Stock Price - MarketBeat
Canaccord raises Biodesix stock price target on strong test volume - Investing.com India
HC Wainwright Forecasts Biodesix's Q3 Earnings (NASDAQ:BDSX) - MarketBeat
Earnings Update: Here's Why Analysts Just Lifted Their Biodesix, Inc. (NASDAQ:BDSX) Price Target To US$32.67 - webull.com
H.C. Wainwright Maintains Biodesix(BDSX.US) With Buy Rating, Maintains Target Price $27 - Moomoo
Biodesix Inc (BDSX) Stock News Today - TradingKey
Biodesix boosts sales, trims loss as diagnostics firm pushes toward profitability - BizWest
A Quick Look at Today's Ratings for Biodesix(BDSX.US), With a Forecast Between $27 to $40 - Moomoo
Analysts Offer Insights on Healthcare Companies: Biodesix (BDSX), Pacific Biosciences (PACB) and Odyssey Therapeutics, Inc. (ODTX) - The Globe and Mail
BDSX Maintains Buy Rating -- Price Target Raised to $27.00 by HC Wainwright - GuruFocus
바이오데식스 (BDSX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.31%
4.28%
자본화:
|
볼륨(24시간):